MedTrace Logo

Effects of Isotretinoin on CYP2D6 Activity

NCT03076021 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2025-01-28

Study results available
· View outcomes & findings →

Summary

Specific Aim: To investigate if isotretinoin (13-cis-retinoic acid) administration decreases CYP2D6 activity in adolescent patients.

Conditions

  • CYP2D6 Polymorphism

Interventions

DRUG

Isotretinoin

Drug interaction study

DRUG

dextromethorphan

Drug interaction study

Sponsors & Collaborators

Principal Investigators

  • Mary F Hebert, PharmD · University of Washington

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-26
Primary Completion
2023-11-27
Completion
2023-11-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03076021 on ClinicalTrials.gov